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Abstract
OBJECTIVE: The objective of this selective EBM review is to determine whether or not “Is the
combination therapy of clopidogrel (Plavix) and aspirin compared to antithrombotic single
therapy is safe and effective in the prevention of stroke in adults?”
	
  
STUDY	
  DESIGN:	
  Review	
  of	
  three,	
  English	
  language,	
  double-‐blinded,	
  randomized	
  controlled	
  
trial	
  studies	
  with	
  an	
  intention-‐to-‐treat	
  basis	
  published	
  in	
  2004-‐2010.	
  
	
  
DATA	
  SOURCES:	
  	
  Three	
  randomized	
  controlled	
  trial	
  studying	
  the	
  safety	
  and	
  effectiveness	
  
of	
  the	
  combination	
  therapy	
  of	
  clopidogrel	
  (Plavix)	
  and	
  Aspirin	
  compared	
  to	
  antithrombotic	
  
single	
  therapy	
  in	
  the	
  prevention	
  of	
  stroke	
  in	
  adults.	
  
	
  
OUTCOME	
  (S)	
  MEASURED:	
  	
  Outcomes	
  measured	
  were	
  prevention	
  of	
  stroke,	
  which	
  was	
  
measured	
  by	
  randomly	
  assigned	
  patients	
  with	
  evident	
  cardiovascular	
  disease	
  or	
  multiple	
  
risk	
  factors	
  who	
  received	
  clopidogrel	
  plus	
  low	
  dose	
  aspirin	
  or	
  placebo	
  plus	
  low	
  dose	
  
antithrombotic.	
  These	
  were	
  then	
  followed	
  during	
  a	
  28-‐month	
  period	
  while	
  observing	
  the	
  
number	
  of	
  strokes	
  that	
  occurred	
  within	
  that	
  time	
  period,	
  life-‐threatening	
  or	
  major	
  bleeding	
  
occurrences.	
  	
  Severity	
  of	
  stroke	
  in	
  one	
  study	
  was	
  measured	
  with	
  mRS	
  score	
  at	
  3	
  months	
  
after	
  the	
  stroke	
  in	
  one	
  study.	
  The	
  (mRS)	
  Modified	
  Rankin	
  Scale	
  is	
  defined	
  as	
  the	
  functional	
  
severity	
  of	
  the	
  first	
  stroke	
  outcome	
  event	
  at	
  3	
  months	
  after	
  the	
  event.	
  It	
  is	
  measured	
  by	
  
assessing	
  all	
  ADLs	
  patients	
  could	
  actually	
  do	
  (waking,	
  bathing,	
  dressing,	
  grooming)	
  after	
  a	
  
stroke.	
  Data	
  was	
  analyzed	
  on	
  an	
  intention-‐to-‐treat	
  basis.	
  The	
  other	
  two	
  studies	
  measured	
  
the	
  risk	
  of	
  life-‐threatening	
  or	
  major	
  bleeding	
  by	
  the	
  number	
  of	
  occurrences	
  during	
  a	
  28	
  
month	
  follow	
  up.	
  	
  
	
  
RESULTS:	
  	
  The	
  articles	
  reviewed	
  showed	
  that	
  there	
  was	
  no	
  significant	
  benefit	
  associated	
  
with	
  clopidogrel	
  (Plavix)	
  plus	
  aspirin	
  as	
  compared	
  with	
  antithrombotic	
  single	
  therapy	
  in	
  
reducing	
  the	
  incidence	
  of	
  stroke.	
  Furthermore,	
  in	
  the	
  article	
  by	
  Bhatt	
  showed	
  how	
  the	
  risk	
  
of	
  moderate	
  –to-‐severe	
  bleeding	
  was	
  increased	
  	
  
	
  
CONCLUSION:	
  Based	
  on	
  the	
  articles	
  reviewed,	
  the	
  difference	
  between	
  clopidogrel	
  and	
  
aspirin	
  was	
  not	
  statistically	
  significant	
  or	
  more	
  effective	
  than	
  single	
  antithrombotic	
  therapy	
  
alone	
  in	
  reducing	
  the	
  rate	
  of	
  stroke.	
  	
  Furthermore	
  the	
  use	
  of	
  combination	
  therapy	
  
increased	
  the	
  risk	
  of	
  moderate	
  to	
  severe	
  bleeding.	
  	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  

	
  

Clopidogrel	
  and	
  aspirin	
  stroke	
  prevention,	
  Masviba	
  1	
  

INTRODUCTION	
  
Stroke is an acute neurologic injury that occurs as a result of either ischemia due to thrombosis,
embolism or systemic hypoperfusion or due to brain hemorrhage. Approximately 80 percent of
strokes are due to ischemic cerebral infarction and the remaining 20 percent to brain hemorrhage.
Ischemic stroke is known to be caused by the occlusion of an intracranial vessel that causes
diminished supply of arterial blood resulting in ischemia and a lack of oxygen and glucose to
brain tissue. Of the three subtypes of brain ischemia thrombosis generally refers to local in situ
obstruction of an artery due to disease of the arterial wall for example atherosclerosis. Embolism
can result from debris originating from elsewhere for example those with atrial fibrillation.
Ischemic stroke may occur in patients with atrial fibrillation either as an initial presenting
manifestation of atrial fibrillation or despite antithrombotic prophylaxis. Cardiac embolis most
commonly originate from the left atrium, which lead to ischemia and systemic hypoperfusion.4
The patient often has a history of hypertension, diabetes mellitus, valvular heart disease or
atherosclerosis.
The symptoms of brain ischemia may be transient; lasting seconds to minutes, or may persist for
longer periods of time. Signs and symptoms of stroke unfortunately remain indefinitely if the
brain becomes irreversibly damaged and infarction occurs. Unfortunately patient’s neurological
symptoms do not necessarily reflect the presence or the absence of infarction and the symptoms
may not indicate the cause of the ischemia that leads to stroke. It is therefore critical for
providers to accurately identify the cause of the symptoms because treatment as well as
prevention depends upon accurately identifying the cause of symptoms.4 The impact of stroke
can be devastating affecting physical, cognitive, emotional function and lifestyle.
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Stroke causes mortality in almost 130, 000 Americans each year which comes to 1 in
every 19 deaths. The number of stroke deaths is projected to double by 2030 due to the increase
in the elderly population. Approximately 87 % of strokes are ischemic with the remaining 13%
being hemorrhagic therefore the prevalence being so high crosses over into various scopes of the
PA areas of practice and it is vital for providers not only to accurately treat but also prevent the
incidence of stroke. 5,6 According to the Center for Disease Control stroke costs the United States
and estimated $38.6 billion each year. This total includes the cost of health care services,
medications, and missed days of work. Unfortunately there have not been any current studies
done for hospitalizations within the last few years for stroke although past studies from the CDC
showed an increase from 1989 having 800,000 as compared to 1999 and 2009 which both had
almost 1 million. Hospitalizations were for patients who were 65 years and older. 5
In instances of acute stroke patients are treated with thrombolytics if symptoms are within three
hours of onset and hemorrhagic stroke has been ruled out by a CT scan. Anticoagulation is the
most effective long-term antithrombotic therapy for the prevention of recurrent stroke. Currently
Warfarin is the most studied antithrombotic therapy for the prevention of stroke in patients with
atrial fibrillation and an ischemic stroke and its efficacy is well demonstrated. Warfarin acts by
inhibiting a vitamin K complex that required for coagulation factors therefore by depleting
functional vitamin K reserves warfarin reduces synthesis of active clotting factors. Patients are
required to continually have their INR monitored once placed on warfarin. Dual antiplatelet
therapy has also been studied to be a reasonable alternative to therapy with 4 Aspirin having a
mechanism of action that works by irreversibly inhibiting cyclooxygenase-1 and 2 (COX1and2)
enzymes via acetylation which eventually causes inhibition of platelet aggregation. Clopidogrel
functions by blocking receptors on the platelet surface which prevents activation of the
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GPIIb/IIIa receptor complex thereby reducing platelet aggregation. Current research and data has
shown low dose aspirin to reduce ischemic outcomes and recurrence in patients and clopidogrel
(Plavix) has been also studied separately to reduce stroke recurrence rate by 30 percent.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not “ Is the combination
therapy of clopidogrel (Plavix) and Aspirin compared to antithrombotic single therapy safe and
effective in the prevention of stroke in adults”
METHODS
A detailed study was completed by the author using key words clopidogrel (Plavix),
Aspirin and stroke. The articles that were used focused primarily on outcomes of importance to
the patient (Patient Oriented Evidence that matters, or POEMS). The search engines used were
via PubMed and all articles were published in English and all were published in peer-reviewed
journals. Randomized control trials were searched for the following inclusion criteria: Patients
between the ages of 18 and older who have had one of the following: Multiple atherothrombotic
risk factors, documented coronary disease, high risk vascular patients who experienced at least
one previous TIA or an ischemic stroke. A total of three studies were used that were all
randomized, double-blinded controlled trial with an intention to treat bases and one study being a
multicenter multinational study. These compared the combination therapy of clopidogrel and
aspirin to a single antithrombotic therapy or to aspirin alone. The standard dosage of 75mg of
clopidogrel was used in all three studies with low dose aspirin dose varying from 75 to 162mg
per day or placebo plus low dose aspirin. There were also certain exclusion criteria of patients
who had severe comorbid conditions, increased risk of bleeding with clinical evidence of severe
hepatic insufficiency, current peptic ulceration, history of symptomatic bleeding. Table 1
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demonstrates the demographics or the studies included: Statistics were reported using p-values,
relative risk increase (RRI), absolute risk increase (ARI) and number needed to harm (NNH).
OUTCOMES MEASURED
The outcomes measured in all three studies analyzed the overall intervention of
clopidogrel and aspirin compared to a single antithrombotic therapy such as aspirin alone or
other antiplatelet agent. Follow up evaluations were performed in the Bhatt article at one month,
three months, and six months and every six months thereafter until the end of the trial. Data in
this trial was analyzed on an intention –treat basis. In the article by Hankey outcomes were
measured using the Modified Rankin scale (mRS) score, which was assessed by incorporating
all the activities the patients could do 3 months after having a stroke. These activities included
patients having the ability to walk, bathe, dress and groom themselves. Data was also analyzed
with an intention to treat basis. In the article by Diener the outcome was measured by the first
occurrence of an event as an ischemic stroke during an 18 month follow up period a scheduled at
1,3,6,12, and 18 month follow up. The outcome for life-threatening bleeding was also measured
at the same times. This was defined as a drop in hemoglobin of greater than 50g/L, significant
hypotension with need for inotropes, symptomatic intracranial hemorrhage or a transfusion of
less than 3 units of red-blood cells or equivalent amount of whole blood. In all three studies
analysis was based on first occurrence of an ischemic event at any period during the follow-up
period. Several covariables including age, sex and ethnic origin for potential effects on the
primary endpoint including possible interactions with treatment were regarded. This paper
evaluates the intervention of the combination of clopidogrel and aspirin in altering the rate and
functional severity of stroke among high risk patients using number of occurrences during a 28
month follow-up period.
Table 1: Demographics & Characteristics of included studies

Clopidogrel	
  and	
  aspirin	
  stroke	
  prevention,	
  Masviba	
  5	
  

Study

Type

#Pts

Age
(yrs)
> 45
years

Inclusion
Criteria
Adults > 45
years or older
with either
clinically
evident
cardiovascular
disease or
multiple risk
factors
including
stroke

Bhatt
2006

Randomized
,double
blinded,
placebocontrolled
trial

15, 603

Diener
HC
2004

Randomized
, double
blinded,
placebo
controlled
trial

7599

18- 75
years

15, 603

65 +/10
years

Ischemic stroke
or TIA in
previous 3
months and
had 1 or more
of the
additional risk
factors:
Previous
ischemic
stroke, MI,
angina
perctoris
DM,
symptomatic
peripheral
artery disease;
all of the above
within the last
3 years
Age 65 +/- 10
all high
vascular risk
patients who
experienced at
least 1 previous
TIA or
ischemic stroke
- diagnosis of
documented
cerebrovascular
disease

Hankey
GJ
2010

Multicenter,
multinationa
l,
Randomized
, parallel
group,
double
blinded trial

Exclusion
Criteria
-Patients taking
oral
antithrombotic
medication or
NSAIDs on a
long-term basis
(cox2 inhibitors
were permitted)
-Indications for
clopidogrel
therapy such as
recent acute
coronary
syndrome
- vascularization
Contraindicated
for aspirin or
clopidogrel
Age <40 years
Severe comorbid
conditions
Incresed risk of
bleeding (clinical
evidence of
severe hepatic
insufficiency)
History of
systemic bleeding
Other history of
bleeding,
diathresis or
coagulopathy
Scheduled for
major surgery or
vascular surgery
Patients 65 +/- 10
yrs with a
previous
disabling
condition such
that they were
bedridden or
demented were
excluded from
the trial.

W/D

Interventions

0

Regimen to
receive
clopidogrel
(75mg per
day) plus
low dose
Aspirin (75162mg per
day) or to
receive
placebo plus
low-dose
aspirin

270
disc
onti
nued
treat
men
t

Regimen of
Aspirin (75
mg/per day)
and
clopidogrel
(75mg
per/day) or
receive
placebo and
clopidogrel
(75mg)

0

Regimen of
clopidogrel
(Plavix) 75
mg per/day)
plus lowdose ASA (
75-162mg
per/day)
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RESULTS
This EBM review was completed on three randomized double-blinded controlled trials (RCTs).
In the study by Diener the follow up period was 18 months, and the other two studies were a 28
month period. Two of the articles used were presented with dichotomous data outcomes and one
using continuous data. Medication dosed was the same for clopidogrel with the Aspirin dosage
ranging from low dose of 75mg to 162mg or to placebo plus low dose aspirin in the Bhatt study
and Hankey study, with follow up evaluations performed at 1, 3, 6 months and every 6 months
thereafter until the end of the trial. In the Diener study patients were randomly allocated either
75mg of clopidogrel with aspirin 75mg or a matching placebo tablet. This study continued for a
total of 18 months with follow up visits at 1,3,6,12 and 18 months. All the patients in the studies
used were 18 years of age or older. For greater understanding of the calculations used in these
articles it is important to understand the statistical calculations used to prove or disprove the
efficacy of each study and intervention. The efficacy rate for each intervention was calculated
with clopidogrel and aspirin being the experimental event rate (EER) and placebo plus aspirin or
placebo alone being the Controlled Event Rate (CER). The EER and CER was then used to
calculate the Relative Benefit increase (RBI) and Absolute Benefit Increase (ABI). The ABI,
which is interpreted as the absolute arithmetic difference in good outcomes between the
experimental and control groups, was then used to calculate the Numbers Needed to Treat
(NNT). This number is what is crucial to the provider and clinician as it demonstrates the
number of patients needed to be treated in order to obtain one additional good outcome when
being compared to the control medication. For the data given as continuous data the test statistic
was used to describe the method used to obtain the data in which a mRS score which
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demonstrated the physical ability of the patient after having a stroke was used. All three studies
incorporated visually matched placebo in their analysis. The primary endpoint in all three studies
was that of the first occurrence of an ischemic stroke or rehospitalization for an acute ischemic
event.
In the Bhatt et al. 2006 study 15,603 patients with either clinically evident multiple
atherosclerosis and established cardiovascular disease, or multiple risk factors received
clopidogrel. Patients in this study had a mean age of 64 years old of which 29.8% were women.
The groups divided were 7802 on clopidogrel plus aspirin and 7801 on visually matched placebo
plus aspirin. Treatment was permanently discontinued by 20.4% of those in the clopidogrel
group as compared with 18.2% in the placebo group giving a p-value of (P<0.001). A total of
4.8% of the patients in the clopidogrel group and 4.9% of those in the placebo group
discontinued treatment because of an adverse event give a p-value of (P=0.67). Efficacy end
point was completed in 99.5% of the patients of the patients randomly assigned to receive
clopidogrel and aspirin and 99.6% of those randomly assigned to receive placebo and aspirin.
The adverse event included the first occurrence of stroke as well as MI or cardiovascular cause.
The efficacy end point results with a median of 28 months of follow up showed the primary
event rate or EER to be 6.8% in the clopidogrel group and 7.3% in the placebo group the relative
risk was 0.93 and a 95% CI, 0.83 to 1.05, the p-value was P=0.22. The first occurrence of stroke,
TIA as well as other events such as MI, death from cardiovascular causes or hospitalization for
unstable angina was 16.7% in the clopidogrel group and 17.9% in the placebo group. The
relative risk was 0.92; 95% CI, 0.86 to 0.995; and a p-value of P=0.04. The rate of primary safety
end points such as severe bleeding was 1.7% in the clopidogrel group and 1.3% in the placebo
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group with a relative risk of 1.25%; 95% CI, 0.97 to 1.61; and a p-value of P=0.09. 1 The results
are summarized in Table 2 and Table 3.
In the Diener et al. 2004 study 7599 high risk patients with recent ischemic stroke or TIA in the
previous 3 months. 3802 were allotted placebo and clopidogrel and 3797 aspirin and clopidogrel.
In this study the efficacy end point results with a median of 18 months follow up showed the
primary event rate or EER to be 15.7% in the clopidogrel group and 16.7% in the placebo and
clopidogrel group. Relative risk was 6.4% and a 95% CI, (-4.6 to 16.3) the p-value being
P=0.244. Life-threatening bleedings were higher in groups receiving aspirin and clopidogrel
versus those receiving placebo and clopidogrel which had an EER of 2.6 for the clopidogrel and
aspirin and a CER of 1.3 the absolute risk increase ARI was 1.3 % with a 95% CI.2
In the Hankey et al. study the modified Rankin Scale (mRS) score was also used at 3 months
post stroke was assessed demonstrating the outcome of the functional severity of stroke. Among
the 4320 patients who had a qualifying diagnosis of TIA or ischemic stroke for the study 233
(5.4%) of them experienced a stoke during the follow up of whom 103 were randomly assigned
clopidogrel and 130 placebo. The relative risk reduction was 20%, with a 95% CI: -3 % to 38%)
Table 2: clopidogrel +Aspirin vs Placebo +Aspirin response
Clopidogrel Placebo +
P-value
+Aspirin
aspirin
(EER)
(CER)
Bhatt DL (2006) 28
6.8%
7.3%
<0.22
month trial
Diener HC (2004) 18
Clopidogrel Placebo+
P-Value
month trial
+aspirin
Clopidogrel <0.244
15.7%
16.7%
a 95% Confidence Interval

RBI

ABI

NNT

-6.8%

-0.5%

-200a

RBI
5.9%

ABI
-1%

NNT
- 100a

Table 3: mRS score of clopidogrel +Aspirin vs placebo + aspirin (dicotomous data)
Clopidogrel
Placebo + aspirin P-value
+Aspirin
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Hankey study
mRS score of 1-2
showed no symptoms or no significant disability
to death
95% CI - 3% to 38%

44%

46%

P = 0.59

In this review of all three studies the safety, tolerability as well as the serious of adverse effects
with use of clopidogrel and aspirin. This was calculated using dichotomous data in two of the
studies. The third study by Hankey assessed severity or harm by use of the mRS score. 3 Tables
4 and 5 summarize the results of these studies.
Table 4: Severe adverse effects data for clopidogrel and aspirin
Clopidogrel Placebo +
+ aspirin
aspirin
(EER)
(CER)
Bhatt DL
1.7%
(2006) 28
month trial
Diener HC 2.6%
(2004) 18
month trial
Both with a 95% CI

Absolute
Risk
Increase
(ABI)
0.4%

Number
needed to
harm
(NNH)
250
patients

P-value

1.3%

Relative
Risk
Increase
(RRI)
30.7%

1.3%

1%

1.3%

77 patients

<0.0001

0.09

Table5: Severe adverse effects for clopidogrel and aspirin using mRS score (continuous data)

Hankey study
mRS score

Number ischemic strokes with
use of clopidogrel +aspirin
202/233 patients
87%

Number of hemorrhagic
storkes with use of clopidogrel
+ aspirin 19/236 patients
8%

DISCUSSION
The major goal of therapy in patients who have experienced a stroke is to prevent a
recurrent stroke and even more so other adverse life altering effects. Antiplatelet and
antithrombotic therapy have had significant results in both the treatment and prevention of
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stroke. In most patients the effectiveness of aspirin alone in preventing antithrombotic events has
been well studied and proved to have great efficacy. Clopidogrel as a single therapy in the
prevention of stroke has also been well studied but has not been proven to have significant
benefit in the prevention of stroke. In these studies it was found that the addition of aspirin to
clopidogrel had a consistent reduction in primary and secondary vascular events but the
difference between the combination therapy as compared to single antithrombotic therapy was
not significant. It was also seen that in patients with established artherothrombotic disease or
who were at high risk for such disease there was no benefit associated with the combination
therapy of clopidogrel and aspirin in reducing the incidence of stroke. The most significant
finding in this study was that the rate of severe bleeding was increased. The most major type of
life-threatening bleeding that was noted was gastrointestinal bleeding as well as intracranial
bleeding in the Diener et al. study.
Although all three studies were able to analyze and prove that there was little to no significance
of prevention in stroke with the use of combination therapy of clopidogrel (Plavix) and aspirin
there were still some limitations found in the studies used. In the Hankey et al study although
the hypothesis and analysis for the clinical trial were prespecified it was a substudy and not the
primary aim of the trial. Patients were included in this analysis of stroke severity on the basis of
an end point and therefore it is not possible to assume that at the beginning of the trial there was
an equal balance in important prognostic factors between the treatment groups. Another
limitation within this study was that the modified Rankin Scale (mRS) which was used to
measure the severity of the stroke with use of activities of daily living was not assessed at the
time of randomization (i.e at baseline) introducing a possibility of there being an imbalance in
the functional status of patients at baseline. In Bhatt et al study the primary end point of the study
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was not primarily stroke but also included myocardial infarction, or death from cardiovascular
causes therefore not making the primary focus of the study stroke and also decreasing the actual
sample size of those in the trial with an end point of stroke. The trial also did not allow for a
measurement or baseline before randomization of the study to accurately be able to determine the
severity once randomization of the trial had begun leading to questioning of statistical data.
CONCLUSION
Therefore in conclusion as shown in previous studies all patients experiencing a stroke or
TIA should receive an antiplatelet drug for secondary stroke prevention. Current guidelines favor
clopidogrel or aspirin but as show with the three randomized control studies the combination of
clopidogrel plus aspirin was not significantly more effective than single antiplatelet or
antithrombotic therapy in the prevention of stroke. Furthermore the risk of moderate to severe
bleeding was increased in all three studies showing no evidence of support in the use of dual
antiplatelet therapy. In conclusion future studies should include randomized controlled trials with
larger sample size and most importantly should begin with a baseline measurement of activities
of daily living patients can do before randomization of the trial has begun. This will allow for a
more accurate statistical significance. Due to the risk of associated bleeding that occurs with
dual antiplatelet interesting future studies could include looking further into patients with preestablished vascular disease who possibly represent those with hyperactive platelets. If this is
concept is found to be true, dual antiplatelet therapy would be associated with greater efficacy
and a lower rate of bleeding in a patients who are symptomatic and less efficacious in patients
with a reduced basal platelet activity who are asymptomatic which would therefore increase the
risk of bleeding complications. However with the current studies and data until proven otherwise
clinicians should avoid dual antiplatelet therapy in the prevention of stroke.
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